Pancreatic Cancer Research

ResearcherJikei University School of MedicineActive in the last 2 years

Masashi Tsunematsu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6953-1801; OpenAlex author ID A5021307641. Sources: OpenAlex.

Their work

Papers
23 (first author 5, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2022: 1 paper · 2023: 5 papers · 2024: 4 papers · 2025: 8 papers · 2026: 5 papers

Papers 23

  1. Number of Liver Metastases Stratifies Prognosis in Synchronous Metastatic Pancreatic Cancer. Co-author DOI 10.1002/wjs.70666↗
  2. The Goddard score for emphysema predicts the postoperative prognosis in pancreatic cancer. Co-author DOI 10.1007/s00595-025-03188-7↗
  3. Prognostic stratification of unresectable locally advanced pancreatic cancer using a combination of inflammatory and nutritional indices: a retrospective cohor… First author DOI 10.1007/s00595-026-03344-7↗
  4. Preoperative predictors of early recurrence after neoadjuvant gemcitabine plus S-1 in resectable pancreatic cancer: a multicenter study. Co-author DOI 10.1007/s00595-026-03416-8↗
  5. Larger Non-metastatic No. 8 Lymph Node Size Is Associated With Favorable Prognosis After Pancreaticoduodenectomy for Pancreatic Cancer. Co-author DOI 10.21873/cdp.10600↗
  6. Abdominal aortic calcification volume as a preoperative prognostic predictor for pancreatic cancer. Co-author DOI 10.1007/s00595-024-02882-2↗
  7. The minimum apparent diffusion coefficient value on preoperative magnetic resonance imaging in resectable pancreatic cancer: a new prognostic factor for biolog… First author DOI 10.1007/s00595-025-03050-w↗
  8. The preoperative cachexia index predicts outcomes after pancreatic resection for resectable pancreatic cancer. Co-author DOI 10.1007/s00595-025-03088-w↗
  9. Timing of TS1 adjuvant chemotherapy as a prognostic factor in recurrent pancreatic cancer after surgery. Co-author DOI 10.1016/j.suronc.2024.102179↗
  10. Signal heterogeneity in apparent diffusion coefficient map of magnetic resonance imaging in resectable pancreatic cancer: a new prognostic factor for biologica… First author DOI 10.1016/j.suronc.2025.102270↗
  11. Impact of Preoperative Osteosarcopenia and Postoperative Administration of Pancrelipase on the Prognosis of Borderline Resectable and Unresectable Locally Adva… Co-author DOI 10.1177/00031348241272420↗
  12. Prognostic Impact of a Decrease in Serum Carbohydrate Antigen 19-9 Levels After Preoperative Therapy for 4 Months or More for Borderline Resectable Pancreatic … First author DOI 10.1177/00031348241278016↗
  13. Changes in Skeletal Muscle Volume During Preoperative Chemotherapy Affect the Outcome of Pancreatic Cancer. Co-author DOI 10.1177/00031348241278021↗
  14. Prognostic significance of occult vertebral fracture in patients undergoing pancreatic resection for pancreatic cancer. Co-author DOI 10.1016/j.pan.2024.01.003↗
  15. The prognosis-based classification model in resectable pancreatic cancer. First author DOI 10.1016/j.suronc.2024.102035↗
  16. Effect of Risk Factor Score on Early Recurrence After Pancreatectomy for Invasive Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.16968↗
  17. Effect of Chemoradiotherapy on Locoregional Recurrence After Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17229↗
  18. Systemic inflammation adversely affects response to anamorelin in patients with pancreatic cancer. Co-author DOI 10.1007/s00520-023-08206-3↗
  19. Superior mesenteric vein/portal vein contact in preoperative imaging indicates biological malignancy in anatomically resectable pancreatic cancer. Co-author DOI 10.1016/j.suronc.2023.101998↗
  20. The Impact of Fibrinogen to Prognostic Nutritional Index Rate on Prognosis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1177/00031348231204912↗
  21. D1 Distal Pancreatectomy for Left-sided Pancreatic Ductal Adenocarcinoma Is Justifiable: A Propensity-score Matched Multicenter Study. Co-author DOI 10.21873/anticanres.16150↗
  22. Preoperative Therapy for Unresectable Locally Advanced Pancreatic Cancer for ≥6 Months Improves Prognosis After Pancreatectomy. Co-author DOI 10.21873/anticanres.16599↗
  23. The effectiveness of adjuvant chemotherapy for Stage I pancreatic cancer based on the UICC 8th edition. Co-author DOI 10.1007/s00423-022-02686-3↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Toru Ikegami · 23 shared papers, 2022–2026 · strength 5.07
  2. Kenei Furukawa · 22 shared papers, 2022–2026 · strength 4.91
  3. Yoshihiro Shirai · 22 shared papers, 2022–2026 · strength 4.83
  4. Koichiro Haruki · 21 shared papers, 2022–2026 · strength 4.64
  5. Shinji Onda · 18 shared papers, 2022–2026 · strength 3.90
  6. Michinori Matsumoto · 16 shared papers, 2023–2026 · strength 3.53
  7. Ryoga Hamura · 13 shared papers, 2022–2026 · strength 2.71
  8. Takeshi Gocho · 12 shared papers, 2022–2026 · strength 2.58
  9. Norimitsu Okui · 9 shared papers, 2023–2026 · strength 2.09
  10. Mitsuru Yanagaki · 8 shared papers, 2023–2026 · strength 1.89
  11. Tadashi Uwagawa · 8 shared papers, 2022–2026 · strength 1.58
  12. Kyohei Abe · 7 shared papers, 2023–2025 · strength 1.39
  13. Yoshiaki Tanji · 6 shared papers, 2023–2026 · strength 1.28
  14. Tadashi Uwagawa · 5 shared papers, 2024–2025 · strength 1.19
  15. Tomohiko Taniai · 5 shared papers, 2023–2026 · strength 1.14
  16. Taro Sakamoto · 5 shared papers, 2023–2026 · strength 1.05
  17. Yuta Yamada · 4 shared papers, 2024–2026 · strength 1.01
  18. Shuichi Fujioka · 4 shared papers, 2022–2025 · strength 0.70
  19. Shunta Ishizaki · 3 shared papers, 2023–2025 · strength 0.63
  20. Yosuke Igarashi · 2 shared papers, 2023–2025 · strength 0.39
  21. Hironori Shiozaki · 2 shared papers, 2023–2024 · strength 0.35
  22. Takashi Aida · 1 shared paper, 2026 · strength 0.26
  23. Yuki Fujiwara · 1 shared paper, 2022 · strength 0.13
  24. Hiroaki Shiba · 1 shared paper, 2022 · strength 0.13

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.